News and Trends 18 Nov 2022 New discovery gives hope in fight against metastatic cancer Cancer that splits and develops in new organs around the body becomes significantly more difficult to fight. Researchers at Chalmers University of Technology, Sweden, have shown that these metastatic cancers, which spread from the original, adapt their metabolism to the tissue in which they grow. The discovery represents a breakthrough for the understanding of metastatic […] November 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […] November 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Astellas meets primary endpoint in gastric cancer study Astellas Pharma Inc. has announced positive topline results from its phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil). Zolbetuximab is an investigational first-in-class monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, […] November 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Immutep announces efti clinical results for non-small cell lung cancer Immutep Limited has revealed what it says are compelling new clinical data from its TACTI-002 all-comer PD-L1 phase II trial evaluating Immutep’s lead product candidate, eftilagimod alpha in combination with MSD’s (Merck and Co., Inc., Rahway, N.J., USA) anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients with non-small cell lung cancer (NSCLC). The new data was […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The collaboration covers multiple targets from a diverse range of target classes to address diseases with high unmet need. The company also announced the close of […] November 15, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Researchers create mini ‘bone marrow in a dish’ to boost anti-cancer treatments Scientists from Oxford University and the University of Birmingham in the U.K. have made the first bone marrow ‘organoids’ that capture the key features of human bone marrow. The technology, which is the subject of a patent application filed by University of Birmingham Enterprise, will allow for the screening of multiple anti-cancer drugs at the […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 First patient dosed in Nouscom colorectal cancer study Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […] November 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Biotheus enters agreement with Hansoh Pharma for bispecific antibody Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus’ EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Fooditive takes world first bee-free honey a step closer Large scale production trials of the first bee-free honey will start in the New Year thanks to Dutch-based ingredients company, Fooditive. The process of mass-producing a bio-identical honey means that the need to intensively farm honeybees will be eliminated and Fooditive aims to beat a scalable, provenanced supply. Not only will it provide the benefits […] November 15, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 HUTCHMED announces positive gastric cancer study results in China HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial was positive, having met one of the primary endpoints of statistically significant improvement in progression-free survival (PFS), which is clinically meaningful. The other […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Priothera’s Mocravimod improves survival for patients with hematological malignancies Priothera, a biotechnology company developing its S1P receptor modulator compound Mocravimod, has announced that positive data from a clinical trial reinforces the potential for the drug to improve survival outcomes for patients with hematological malignancies. The study has been evaluating Mocramivod in allogeneic hematopoietic cell transplantation patients and was published in journal Transplantation and Cellular […] November 14, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email